{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:57:49Z","timestamp":1790855869348,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T00:00:00Z","timestamp":1322265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10557-011-6349-x","type":"journal-article","created":{"date-parts":[[2011,11,25]],"date-time":"2011-11-25T04:46:06Z","timestamp":1322196366000},"page":"57-65","source":"Crossref","is-referenced-by-count":44,"title":["Phase III Clinical Pharmacology Study of Tolvaptan"],"prefix":"10.1007","volume":"25","author":[{"name":"for the Tolvaptan Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inomata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,26]]},"reference":[{"key":"6349_CR1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","volume":"41","author":"A Nohria","year":"2003","unstructured":"Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797\u2013804.","journal-title":"J Am Coll Cardiol"},{"key":"6349_CR2","unstructured":"Japanese Circulation Society. Guidelines for the Treatment of Chronic Heart Failure, 2010. Available at: http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2010_matsuzaki_h.pdf . Accessed 13 April 2011."},{"key":"6349_CR3","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.167586","volume":"112","author":"SA Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH, et al. ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology\/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation. 2005;112:e154\u2013235.","journal-title":"Circulation"},{"key":"6349_CR4","doi-asserted-by":"crossref","first-page":"G8","DOI":"10.1016\/S0195-668X(01)80003-8","volume":"3","author":"I Anand","year":"2001","unstructured":"Anand I, Florea VG. Diuretics in chronic heart failure\u2014benefits and hazards. Eur Heart J Suppl. 2001;3:G8\u2013G18.","journal-title":"Eur Heart J Suppl"},{"key":"6349_CR5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/eurheartj\/ehi176","volume":"26","author":"S Gupta","year":"2005","unstructured":"Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J. 2005;26:644\u20139.","journal-title":"Eur Heart J"},{"key":"6349_CR6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","volume":"2","author":"GM Felker","year":"2009","unstructured":"Felker GM, O\u2019Connor CM, Braunwald E, for the Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2:56\u201362.","journal-title":"Circ Heart Fail"},{"key":"6349_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9149(85)90290-5","volume":"55","author":"Multiple Risk Factor Intervention Trial Group","year":"1985","unstructured":"Multiple Risk Factor Intervention Trial Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple risk factor intervention trial. Am J Cardiol. 1985;55:1\u201315.","journal-title":"Am J Cardiol"},{"key":"6349_CR8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","volume":"100","author":"HA Cooper","year":"1999","unstructured":"Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311\u20135.","journal-title":"Circulation"},{"key":"6349_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","volume":"57","author":"J Bayliss","year":"1987","unstructured":"Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17\u201322.","journal-title":"Br Heart J"},{"key":"6349_CR10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"6349_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","volume":"292","author":"T Hirano","year":"2000","unstructured":"Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288\u201394.","journal-title":"J Pharmacol Exp Ther"},{"key":"6349_CR12","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690\u20136.","journal-title":"Circulation"},{"key":"6349_CR13","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"6349_CR14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized forworsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"key":"6349_CR15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"6349_CR16","doi-asserted-by":"crossref","unstructured":"Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T, for the Tolvaptan Investigators. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther 2011; e-pub ahead of print","DOI":"10.1007\/s10557-011-6303-y"},{"key":"6349_CR17","doi-asserted-by":"crossref","unstructured":"Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovac Drugs Ther 2011; e-pub ahead of print","DOI":"10.1007\/s10557-011-6299-3"},{"key":"6349_CR18","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-011-6349-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-011-6349-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-011-6349-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:18:28Z","timestamp":1741958308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-011-6349-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,26]]},"references-count":18,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["6349"],"URL":"https:\/\/doi.org\/10.1007\/s10557-011-6349-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,26]]}}}